Nemunaitis J J, Singer J W, Sanders J E
Fred Hutchinson Cancer Research Center, Seattle, WA.
Bone Marrow Transplant. 1991;7 Suppl 3:24-7.
Phase I, II trials indicate that Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF), stimulates recovery of neutrophils following myelosuppressive chemoradiotherapy. In Seattle it was administered to patients undergoing autologous bone marrow transplant (ABMT) for lymphoid malignancy. The data indicate that rhGM-CSF was well tolerated and associated with earlier neutrophil recovery, fewer infections and shorter initial hospital duration. Survival was not improved, however, less regimen-related toxicity was observed. Studies in patients with marrow graft failure are strongly suggestive of improved survival and rhGM-CSF is recommended for therapy in those patients. Although numbers were small, results in pediatric patients were not significantly different than results in adults.
I期和II期试验表明，重组人粒细胞巨噬细胞集落刺激因子（rhGM-CSF）可促进骨髓抑制性放化疗后中性粒细胞的恢复。在西雅图，它被用于接受自体骨髓移植（ABMT）治疗淋巴恶性肿瘤的患者。数据表明，rhGM-CSF耐受性良好，与中性粒细胞更早恢复、感染减少和初始住院时间缩短相关。然而，生存率并未提高，观察到的方案相关毒性较小。对骨髓移植失败患者的研究强烈提示生存率有所提高，因此建议rhGM-CSF用于这些患者的治疗。尽管病例数较少，但儿科患者的结果与成人患者的结果没有显著差异。
